Major Upgrades In Store For The US FDA's Inactive Ingredients Database

A US FDA official has announced that major revisions are underway to address problems with the agency’s Inactive Ingredient Database. These include replacing potency limits with a maximum daily exposure limit and adopting standard terminology for routes of administration. In its current form, the IID has been a source of confusion for industry.